According to these reports, there is only one test that they are allowed to run on the proprietary system that is supposed to provide that advantage. All the others are being run using conventional methods.
I understand it as they can still ran all the tests they were running before using other methods to get the blood sample. The only advantage of the nanotainer was its ability to be less invasive.
I think the other factor was supposed to be the cost of the assays. If they're just using the same machines as everyone else to do the same tests, they have no competitive advantage.